The trial focuses on people with advanced Non Small Cell Lung Cancer who also have Interstitial Lung Disease. In the first treatment stage, the chemotherapy drugs carboplatin and paclitaxel are given, sometimes together with the targeted drug bevacizumab. In the second stage, patients may receive another chemotherapy chosen by the doctor or one of the immune‑based medicines pembrolizumab or nivolumab.
The main goal is to see how well the first set of medicines controls the cancer and to assess how the second‑line medicines affect breathing problems caused by the lung disease. Participants receive a series of intravenous infusions over several weeks, followed by regular check‑ups that include blood tests and imaging. Imaging is performed with a CT scan, which is a special X‑ray that creates detailed pictures of the lungs and chest.
After the initial treatment period, patients are monitored for up to six months to record any worsening of breathing that might require stopping the medication, as well as overall health outcomes such as how long the disease stays stable and overall survival. All side effects are recorded and graded according to standard cancer‑treatment safety guidelines. The study follows a set schedule of clinic visits, drug administration, and imaging assessments.
France 
